Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986447
- Development stage
- Phase 1
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BMS-986447 is an investigational small molecule drug developed by Bristol Myers Squibb. It functions as a selective inhibitor of protein kinase C theta (PKCθ), a member of the protein kinase C family involved in T-cell activation and immune response modulation. The drug has been evaluated in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics following single oral doses in healthy adult participants[3][5][9]. As of June 2025, there are no approved indications or known adverse events reported for this compound.
02
Targets
PRKCQ (Protein kinase C theta)
Beyond the preview
Go deeper on BMS-986447.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986447.